Tremfya® (guselkumab)-the first
IL-23 inhibitor for the treatment
of whole psoriatic disease (PsO/PsA).10

5-year skin clerance,8
so patients can get back to feeling their best3		 Read our 5-year efficancy data
5-year safety,8
so clear skin3-5,8-9 comes with peace of mind		 LEARN ABOUT OUR 5-YEAR SAFETY
New indication in Psoriatic Arthritis
improving joint symptoms, so patients can keep moving		 LEARN ABOUT THE ROLE OF IL-23 IN PsA
Simple and convenient administratin,10,11
so patients can enjoy the everyday life they love 		FIND OUT FOR YOURSELF
Results reaffirmed in the real world,12,14
to benefit your patients day-to-day		 REVIEW THE STUDY
Access a world of knowledge about IL-23
in PsO and PsA and more...		 VISIT OUR MEDICAL PLATFORM
 
 

PsO-Psoriasis, PsA-Psoriatic Arthritis.
 
 
 
REFERENCES SEE MORE OF THE LATEST DATA
ON THE JANSSEN MEDICAL CLOUD™		 PRESCRIBING
INFORMATION

 
TREMFYA® is indicated for adults with moderate-to-severe plaque
psoriasis (Pso) who are candidates for systemic therapy.10

Tremfya®, alone or in combination with methotrexate (MTX), is indicated
for the treatment of active psoriatic arthritis in adult patients who have
had an inadequate response or who have been intolerant to a prior
disease-modifying antirheumatic drug (DMARD) therapy. 10

Please ensure you review your local Prescribing Information and/or
Summary of Product Characteristics and directly consult
your local Janssen affiliate to address questions.		 Privacy notice  Legal notice

This is published by Janssen Pharmaceutica NV which is solely responsible
for its content. It is intended for EMEA Healthcare professionals.
Third party trademarks used herein are trademarks of their respective owners.
Date of preparation: March 2021.  CP-214600